PHARMACEUTICAL 2022

Urogen Pharma Ltd
Rank 423 of 471



PHARMACEUTICAL 2022

Urogen Pharma Ltd
Rank 423 of 471

The relative strengths and weaknesses of Urogen Pharma Ltd are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Urogen Pharma Ltd compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 4.4% points.The greatest weakness of Urogen Pharma Ltd is the variable Stockholders Equity, reducing the Economic Capital Ratio by 159% points.

The company's Economic Capital Ratio, given in the ranking table, is 134%, being 141% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	114,390
Cost of Goods Sold	5,157
Intangible Assets	0
Liabilities, Current	22,380
Liabilities, Non-Current	398
Other Assets	3,389
Other Compr. Net Income	-296
Other Expenses	18,740
Other Liabilities	88,555
Other Net Income	212
Other Revenues	48,042
Property and Equipment	1,967
Research and Development	47,642
Selling, General and Administrative Expense	87,535

Output Variable	Value in 1000 USD
Assets	119,746
Liabilities	111,333
Expenses	159,074
Revenues	48,042
Stockholders Equity	8,413
Net Income	-110,820
Comprehensive Net Income	-110,968
BaseVar	219,352
ECR before LimitedLiability	-80%
Economic Capital Ratio	134%